Ironwood Pharmaceuticals Stock News

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an ef...

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% yea...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription ...

CALGARY, AB / ACCESS Newswire / October 24, 2025 / Ironwood Stair & Rail Inc., a company built on craftsmanship and passion, has been recognised with the 2025 Consumer Choice Award in the Stairs and Railings category for Southern Alberta. This recognition highlights Ironwood's reputation for exceptional design, quality, and service in transforming homes and businesses with custom-built stairs a...

Ironwood (IRWD) Q2 EPS Jumps 600%

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand grow...